Business UpdateApr 22, 2026, 08:21 AM
Allarity Presents AACR 2026 Posters on Stenoparib & Ovarian Cancer Data
AI Summary
Allarity Therapeutics announced the publication of two scientific posters presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations highlight stenoparib's potential in colorectal cancer through WNT pathway modulation and new predictive data linking the Stenoparib-DRP® companion diagnostic to enhanced overall survival in ovarian cancer patients. These findings underscore the company's ongoing research and development efforts for its lead drug candidate.
Key Highlights
- Allarity presented two scientific posters at AACR Annual Meeting 2026.
- Posters highlight stenoparib's potential in colorectal cancer via WNT pathway modulation.
- Stenoparib-DRP® companion diagnostic linked to enhanced overall survival in ovarian cancer patients.
- AACR Annual Meeting 2026 was held from April 17-22 in San Diego, California.
Price Impact
More from ALLR